In the present study, we found that 28-week FLA treatment notably alleviated NASH development in NAFL model mice fed with an HFD, and the beneficial effects may be attributed to the regulation of and improvement in the gut flora and microbiota related BAs, which then activate the intestinal FXR-FGF15 and TGR5-NF-κB pathways. The gene discussed is GPBAR1; the disease is metabolic dysfunction-associated steatohepatitis.